ASX:AGNPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals
Argenica Therapeutics Ltd
$0.175
+$0.025 (+16.67%)
Day Range
$0.160 – $0.175
52 Week Range
$0.087 – $0.770
Volume
181.39K
Avg Volume (10D)
192.77K
Market Cap
$22.48M
Price Chart
Market Statistics
Open$0.160
Previous Close$0.150
Day High$0.175
Day Low$0.160
52 Week High$0.770
52 Week Low$0.087
Valuation
Market Cap22.48M
Shares Outstanding128.46M
Price to Book5.60
Trading Activity
Volume181.39K
Value Traded31.18K
Bid$0.165 × 85,176
Ask$0.175 × 25,209
Performance
1 Day0.00%
5 Day0.00%
13 Week0.00%
52 Week-78.26%
YTD-49.15%
Technical Indicators
RSI (14)65.80
50-Day SMA$0.129
200-Day SMA$0.204
Latest News
Biotechnology
Argenica Therapeutics Reports ARG-007 Neuroprotection in Concussion Study
Argenica's ARG-007 delivers durable neuroprotection after repeat mild TBI in a concussion model, hinting at a disease-modifying therapy from a single dose.
Biotechnology
Argenica Therapeutics Establishes Expert Committee to Advance Phase 2b Stroke Trial
Argenica Therapeutics forms Clinical Advisory Committee to accelerate ARG-007 Phase 2b stroke trial.
Biotechnology
Argenica Study Confirms Compatibility of ARG-007 Candidate with Stroke Treatment Standard-of-Care Therapies
Argenica Therapeutics (ASX: AGN) has reported positive results from a drug-to-drug interaction assessment showing its lead candidate ARG-007 does not interfere with clot-dissolving agent tenecteplase in the treatment of acute ischemic stroke.
Biotechnology
Argenica Therapeutics Validates Efficacious ARG-007 Dose in New Pre-Clinical Stroke Study
Argenica Therapeutics (ASX: AGN) has released new data from an independent pre-clinical study validating the efficacy and dosing of lead neuroprotective peptide candidate ARG-007 for ischaemic stroke.